Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyvalent Vaccine-KLH + OPT-821 in Ovarian Cancer
NCT00693342Phase 3Withdrawn
- Sponsor
- GOG Foundation
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised trial of polyvalent antigen-KLH conjugate vaccine in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by GOG Foundation. Primary endpoint: Progression-free survival. Status: withdrawn.
02
Drugs
polyvalent antigen-KLH conjugate vaccine
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00693342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00693342.